• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Meda AB - Product Pipeline Review - Q2 2011 Product Image

Meda AB - Product Pipeline Review - Q2 2011

  • Published: July 2011
  • Region: Global
  • 81 pages
  • Global Markets Direct

Meda AB – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Meda AB - Product Pipeline Review - Q2 2011” provides data on the Meda AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Meda AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Meda AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Meda AB - Brief Meda AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Meda AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles READ MORE >



List of Tables
List of Figures
Meda AB Snapshot
Meda AB Overview
Key Information
Key Facts
Meda AB – Research and Development Overview
Key Therapeutic Areas
Meda AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Meda AB – Pipeline Products Glance
Meda AB – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Meda AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Meda AB – Drug Profiles
Dymista
Product Description
Mechanism of Action
R&D Progress
Onsolis
Product Description
Mechanism of Action
R&D Progress
Sotirimod
Product Description
Mechanism of Action
R&D Progress
Meda AB – Pipeline Analysis
Meda AB – Pipeline Products by Therapeutic Class
Meda AB - Pipeline Products By Target
Meda AB – Pipeline Products by Route of Administration
Meda AB – Pipeline Products by Molecule Type
Meda AB – Recent Pipeline Updates
Meda AB – Company Statement
Meda AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Meda AB, Deals Volume Summary, 2004 to YTD 2011
Meda AB, Deals Summary By Region, 2004 to YTD 2011
Meda AB, Deals Summary, 2004 to YTD 2011
Meda AB Detailed Deal Summary
Asset Purchase
Meda Acquires Rights Of Onsolis From BioDelivery Sciences International
Meda Acquires European Business Operations Of Valeant Pharmaceuticals
Meda Acquires Global Rights Of Pharmaceutical Products From Roche
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Meda Acquires European Rights Of Sotirimod From 3M
Meda Acquires CNS & Cancer Drugs In Europe From Wyeth
Meda Acquires European Pharmaceuticals Division Of 3M
Laboratorios Almirall Acquires Rights And Intellectual Property Of Novolizer From Meda
Meda Acquires European Rights Of Parlodel From Novartis
Meda Acquires Rights Of Imovane From Sanofi-Aventis
Meda Acquires Rights To Cibacen And Cibadrex From Novartis
Meda Acquires Rights Of Cyklokapron And Cyklo-F From Omega Pharma
Acquisition
Meda Acquires Ellem Lakemedel
Meda Acquires Recip From Recipharm
Meda Acquires MedPointe From The Carlyle, The Cypress, Ferrer Freeman And Frazier Healthcare
Meda Acquires VIATRIS From Advent International
BioPhausia Acquires Cross Pharma From Meda
Meda Acquires Ipex Medical
Equity Offering
Meda Completes Rights Offering Of $212 Million
Meda Completes Rights Offering Of $270 Million
Meda Completes Public Offering Of $324 Million
Meda Completes Public Offering Of $80 Million
Meda Expands Co-Marketing Agreement With Ethypharm
Meda Enters Into Co-Development Agreement With Cipla
BioDelivery Sciences Amends Co-Marketing Agreement With Meda
Meda Enters Into An Agreement With ULURU
Meda Extends Its Collaboration Agreement With Recordati
Valeant Pharmaceuticals Enters Into Joint Venture With Meda
BioDelivery Sciences Expands Co-Development Agreement With Meda
Meda Extends Its Agreement With Recordati
Meda Enters Into An Agreement With Ethypharm
Recordati Signs Agreement With Meda
Biodelivery Sciences International Enters Into An Agreement With Meda
Meda Enters Into Agreement With Orion Pharma
Licensing Agreements
EpiCept Enters Into Licensing Agreement With Meda
Biodelivery Sciences International Enters Into Licensing Agreement With Meda
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Meda AB – Pipeline by Therapy Area and Indication, 2011
Meda AB – Pipeline by Stage of Development, 2011
Meda AB – Monotherapy Products in Pipeline, 2011
Meda AB – Filed, 2011
Meda AB - Phase II, 2011
Meda AB - Pipeline By Therapeutic Class, 2011
Meda AB - Pipeline By Target, 2011
Meda AB – Pipeline By Route of Administration, 2011
Meda AB – Pipeline By Molecule Type, 2011
Meda AB – Recent Pipeline Updates, 2011
Meda AB, Other Locations
Meda AB, Subsidiaries
Meda AB, Deals Summary, 2004 to YTD 2011
Meda AB, Deals Summary by Region, 2004 to YTD 2011
Meda AB, Deals Summary, 2004 to YTD 2011
Meda AB, Deals Summary, 2004 to YTD 2011

List of Figures
Meda AB – Pipeline by Therapy Area and Indication, 2011
Meda AB – Pipeline by Stage of Development, 2011
Meda AB – Monotherapy Products in Pipeline, 2011
Meda AB – Pipeline By Therapeutic Class, 2011
Meda AB - Pipeline By Target, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS